2013
Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours
Soria JC, Baselga J, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, Armand JP, Shepherd FA, Harbison CT, Berman D, Park JS, Zhang S, Vakkalagadda B, Kurland JF, Pathak AK, Herbst RS. Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. European Journal Of Cancer 2013, 49: 1815-1824. PMID: 23490650, DOI: 10.1016/j.ejca.2013.02.012.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedArea Under CurveCarcinoma, Non-Small-Cell LungDiarrheaDose-Response Relationship, DrugDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideExanthemaFemaleHumansLung NeoplasmsMaleMetabolic Clearance RateMiddle AgedNeoplasm MetastasisNeoplasmsPiperidinesProtein Kinase InhibitorsPyrrolesQuinazolinesReceptor, ErbB-2Treatment OutcomeTriazinesVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-3ConceptsIIa studyBMS-690514Growth factor receptorPhase IAdverse eventsEGFR mutationsHER-2Phase IIaFrequent treatment-related adverse eventsSolid tumorsTreatment-related adverse eventsOral tyrosine kinase inhibitorDisease controlVascular endothelial growth factor receptorManageable safety profileObjective response rateAdvanced solid tumorsFactor receptorMetastatic solid tumorsEndothelial growth factor receptorCell lung cancerTyrosine kinase inhibitorsInhibition of VEGFREpidermal growth factor receptorWild-type EGFR
2007
Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research 2007, 13: 6175-6181. PMID: 17947484, DOI: 10.1158/1078-0432.ccr-07-0460.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiopsyCarcinoma, Non-Small-Cell LungDimerizationErbB ReceptorsFemaleFluorodeoxyglucose F18HumansLung NeoplasmsMaleMiddle AgedMutationPositron-Emission TomographyProtein Structure, TertiaryReceptor, ErbB-2Time FactorsTreatment OutcomeConceptsNon-small cell lung cancerProgression-free survival ratesCell lung cancerPositron emission tomographyLung cancerRecurrent non-small cell lung cancerHumanized monoclonal anti-HER2 antibodyGrade 4 adverse eventsGrade 4 cardiac toxicityPrimary efficacy end pointEmission tomographyEfficacy end pointPhase II trialResponse Evaluation CriteriaMonoclonal anti-HER2 antibodyOverall response rateMetabolic responseTumor glucose metabolismAnti-HER2 antibodyStable diseaseII trialAdverse eventsCardiac toxicityPharmacodynamic markersCore biopsy
2005
High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor
Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor. Cancer Research 2005, 65: 11478-11485. PMID: 16357156, DOI: 10.1158/0008-5472.can-05-1977.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmErbB ReceptorsGefitinibGenes, rasHumansLigandsLung NeoplasmsMiceMice, KnockoutMutationNeoplasms, Glandular and EpithelialPhosphorylationProto-Oncogene Proteins c-aktQuinazolinesReceptor, ErbB-2Receptor, ErbB-3Tumor Cells, CulturedTyrosineConceptsEpidermal growth factor receptorLung adenocarcinoma patientsLung adenocarcinoma cellsErbB family membersEGFR inhibitionGrowth factor receptorAdenocarcinoma patientsLung adenocarcinomaTumor biopsiesAdenocarcinoma cellsEpithelial neoplastic lesionsHigh expressionFactor receptorGenetic mutationsHuman lung adenocarcinoma cell lineLung adenocarcinoma cell linesAdenocarcinoma cell lineFamily membersNeoplastic lesionsOncogenic KRASErbB ligandsReceptorsAdenocarcinomaPatientsBiopsyTumor Cavitation in Stage I Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome
Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, Vaporciyan AA, Isobe T, Gilcrease MZ, Marom EM. Tumor Cavitation in Stage I Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome. Radiology 2005, 237: 342-7. PMID: 16183941, DOI: 10.1148/radiol.2371041650.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellErbB ReceptorsFemaleFollow-Up StudiesHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisProportional Hazards ModelsRadiography, ThoracicReceptor, ErbB-2Retrospective StudiesSurvival RateTomography, X-Ray ComputedConceptsStage I non-small cell lung cancerNon-small cell lung cancerEpidermal growth factor receptorCell lung cancerSquamous cell carcinomaCavitary lesionsTumor diameterCell carcinomaLung cancerSurvival timePathologic stage I non-small cell lung cancerEGFR overexpressionProportional hazards regression modelsShorter disease-free survival timeShorter overall survival timeDisease-free survival timeEpidermal growth factor receptor expressionFindings of chestGrowth factor receptor expressionMedian overall survivalOverall survival timeHazards regression modelsPresence of calcificationFactor receptor expressionInstitutional review boardCurrent Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy
Isobe T, Herbst RS, Onn A. Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy. Seminars In Oncology 2005, 32: 315-328. PMID: 15988686, DOI: 10.1053/j.seminoncol.2005.02.016.Peer-Reviewed Original ResearchMeSH KeywordsAlkyl and Aryl TransferasesAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCyclooxygenase InhibitorsDrug Delivery SystemsErbB ReceptorsFarnesyltranstransferaseHumansLung NeoplasmsMatrix Metalloproteinase InhibitorsProtein Kinase CReceptor, ErbB-2Receptors, Vascular Endothelial Growth FactorRetinoid X ReceptorsConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerLung cancerVascular endothelial growth factorEpidermal growth factor receptorBiological therapyGrowth factorLung cancer patientsCancer-related deathLung cancer progressionClinical study designNew therapeutic strategiesEndothelial growth factorGrowth factor receptorOverall prognosisPatient survivalStandard treatmentCancer patientsConventional chemotherapyFrequent causeRadiation therapyTherapeutic approachesAnticancer arsenalTherapeutic strategies
2004
Review of epidermal growth factor receptor biology
Herbst RS. Review of epidermal growth factor receptor biology. International Journal Of Radiation Oncology • Biology • Physics 2004, 59: s21-s26. PMID: 15142631, DOI: 10.1016/j.ijrobp.2003.11.041.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorSignal transduction pathwaysSmall molecule inhibitorsTransduction pathwaysSubsequent activationReceptor tyrosine kinasesEpidermal growth factor receptor biologyTyrosine kinase phosphorylationEGFR inhibitorsTyrosine kinase receptorsIntracellular portionGrowth factor receptorCommon pharmacologic approachesEGFR activityEGFR activationExtracellular domainTyrosine kinaseKinase phosphorylationKinase receptorsCognate ligandsTransmembrane glycoproteinReceptor biologyErbB familyTumor cell linesCellular proliferationTrastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease
Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004, 44: 99-110. PMID: 15013588, DOI: 10.1016/j.lungcan.2003.09.026.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEnzyme-linked immunosorbent assayCell lung cancerSerum HER2Stage IIIBIHC 3Lung cancerHER2 scoreDay oneIHC analysisAdvanced non-small cell lung cancerPharmacokinetics of trastuzumabAddition of trastuzumabPhase II trialSerum enzyme-linked immunosorbent assayGemcitabine 1250Trastuzumab trialsChemonaive patientsII trialPartial responseHER2 overexpressingTrastuzumab therapyMedian timeAntigen levelsHER2 expressionSynchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer
Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O’Reilly M, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. Clinical Cancer Research 2004, 10: 136-143. PMID: 14734462, DOI: 10.1158/1078-0432.ccr-0373-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDisease ProgressionErbB ReceptorsFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPhosphorylationPrognosisReceptor, ErbB-2Retrospective StudiesRisk FactorsSurvival RateTransforming Growth Factor alphaConceptsStage I non-small cell lung cancerNon-small cell lung cancerEpidermal growth factor receptorCell lung cancerSquamous cell carcinomaHER2-neuGrowth factor alphaPhosphorylated epidermal growth factor receptorGrowth factor receptorCell carcinomaLung cancerFactor alphaPathological stage I non-small cell lung cancerFactor receptorPotential prognostic factorsShorter overall survivalPatients' clinical outcomesSynchronous overexpressionHER2-neu overexpressionLung cancer progressionMaximal therapyMetastatic diseaseOverall survivalPrognostic factorsClinical outcomes